3-[4-(3-Hydroxyphenyl)sulfanyl-2,3-bis(trifluoromethyl)phenyl]-1-morpholin-4-ylprop-2-en-1-one | 869099-04-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3-[4-(3-Hydroxyphenyl)sulfanyl-2,3-bis(trifluoromethyl)phenyl]-1-morpholin-4-ylprop-2-en-1-one
• CAS: 869099-04-7
• 化学式: C₂₁H₁₇F₆NO₃S
• 分子量: 477.427
• InChiKey: JFPZOGUMXVXLPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  75.1
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  2-吡啶甲醇 、 3-[4-(3-Hydroxyphenyl)sulfanyl-2,3-bis(trifluoromethyl)phenyl]-1-morpholin-4-ylprop-2-en-1-one 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 生成 1-Morpholin-4-yl-3-[4-[3-(pyridin-2-ylmethoxy)phenyl]sulfanyl-2,3-bis(trifluoromethyl)phenyl]prop-2-en-1-one
  参考文献：
  名称：

  Structure–activity relationship of ortho- and meta-phenol based LFA-1 ICAM inhibitors

  摘要：

  LFA-1 ICAM inhibitors based on ortho- and meta-phenol templates were designed and synthesized by Mitsunobu chemistry. The selection of targets was guided by X-ray co-crystal data, and led to compounds which showed an up to 30-fold increase in potency over reference compound 1 in the LFA-1/ICAM1-Ig assay. The most active compound exploited a new hydrogen bond to the I-domain and exhibited subnanomolar potency. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.062
• 作为产物：
  描述：

  [4-(3-Morpholin-4-yl-3-oxoprop-1-enyl)-2,3-bis(trifluoromethyl)phenyl] trifluoromethanesulfonate 、 3-羟基苯硫酚 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 1.0h， 生成 3-[4-(3-Hydroxyphenyl)sulfanyl-2,3-bis(trifluoromethyl)phenyl]-1-morpholin-4-ylprop-2-en-1-one
  参考文献：
  名称：

  Structure–activity relationship of ortho- and meta-phenol based LFA-1 ICAM inhibitors

  摘要：

  LFA-1 ICAM inhibitors based on ortho- and meta-phenol templates were designed and synthesized by Mitsunobu chemistry. The selection of targets was guided by X-ray co-crystal data, and led to compounds which showed an up to 30-fold increase in potency over reference compound 1 in the LFA-1/ICAM1-Ig assay. The most active compound exploited a new hydrogen bond to the I-domain and exhibited subnanomolar potency. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.062

文献信息

• Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them
  申请人：Guckian Kevin

  公开号：US20080234271A1

  公开（公告）日：2008-09-25

  The present invention relates in part to compounds of formulas (I) and (III): and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject.

  本发明部分涉及式(I)和式(III)化合物及其药学可接受的盐和前药。这些化合物可用于治疗炎症和免疫疾病等疾病。本发明还涉及包含这些化合物的制药组合物，以及抑制主体中的炎症或抑制免疫反应的方法。
• Arylphenylamino-,Arylphenylamide-, and Arylphenylether-Sulfide Derivatives
  申请人：Chin Donovan

  公开号：US20070259863A1

  公开（公告）日：2007-11-08

  The present invention relates in part to compounds of formulas I and III: and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject.

  本发明部分涉及式I和式III的化合物：以及其药学上可接受的盐和前药。这些化合物可用于治疗炎症和免疫性疾病。本发明还涉及包含这些化合物的制药组合物，以及抑制炎症或抑制受试者免疫反应的方法。
• ARYLPHENYLAMINO-, ARYLPHENYLAMIDE-, AND ARYLPHENYLETHER-SUFIDE DERIVATIVES
  申请人：ICOS Corporation

  公开号：EP1740565A2

  公开（公告）日：2007-01-10
• [EN] ARYLPHENYLAMINO-, ARYLPHENYLAMIDE-, AND ARYLPHENYLETHER-SULFIDE DERIVATIVES<br/>[FR] DERIVES DE SULFURE D'ARYLPHENYLAMINE, D'ARYLPHENYLAMIDE, ET D'ARYLPHENYLETHER
  申请人：ICOS CORP

  公开号：WO2005105770A2

  公开（公告）日：2005-11-10

  The present invention relates in part to compounds of formulas I and III: and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject.
• Structure–activity relationship of ortho- and meta-phenol based LFA-1 ICAM inhibitors
  作者：Edward Yin-Shiang Lin、Kevin M. Guckian、Laura Silvian、Donovan Chin、P. Ann Boriack-Sjodin、Herman van Vlijmen、Jessica E. Friedman、Daniel M. Scott

  DOI：10.1016/j.bmcl.2008.08.062

  日期：2008.10

  LFA-1 ICAM inhibitors based on ortho- and meta-phenol templates were designed and synthesized by Mitsunobu chemistry. The selection of targets was guided by X-ray co-crystal data, and led to compounds which showed an up to 30-fold increase in potency over reference compound 1 in the LFA-1/ICAM1-Ig assay. The most active compound exploited a new hydrogen bond to the I-domain and exhibited subnanomolar potency. (C) 2008 Elsevier Ltd. All rights reserved.